Mild to moderate anaemia Haematological Disorders Anaemia
Conditions
Interventions
1. Iron fortification (biscuitis with two x 10 mg Fe/day/child
four per week)
2. Intermittent preventative treatment (sulfadoxine (500 mg) and pyrimethamine (25 mg)
three times, interval: three-month)
3. Albendazole (400 mg) and praziquantel (40 mg/kg)
three times, interval: three-month
Sponsors
ETH Food Science and Nutrition (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Child, aged six to 14 years, both sexes, attending the local primary school of five selected villages 2. For girls, not pregnant (as assessed by medical doctor) 3. Absence of major systemic illnesses (as assessed by medical doctor upon initial full clinical assessment) 4. Anticipated residence in the study area for at least one year 5. Mild to moderate anaemia defined as Haemoglobin (Hb) more than 80 g/L and less than 115 g/L in children aged between six and 12 years, and Hb more than 80 g/Land less than 120 g/L in children more than or equal to 12 years 6. No known or reported hypersensitivity to albendazole, praziquantel or sulfadoxine-pyrimethamine 7. No known or reported history of significant chronic illness 8. No known history of anthelmintic treatment in the four weeks prior to study enrolment 9. Written informed consent of parents or legal guardian
Exclusion criteria
Exclusion criteria: 1. Hb less than 80g/L 2. Attending any other clinical trials during the study period 3. Presence of any abnormal medical condition, judged by the investigator medical team
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Reduction in anaemia 2. Change in cognitive performance | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of clinical malaria episodes during trial period | — |
Countries
Cote d'Ivoire
Outcome results
None listed